1 recruiting. 1 Phase 2, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 1 | Recruiting 1 |
| Phase 3 | 1 | Recruiting 1 |
Follow Yi Ji: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Low- vs High-Dose Sirolimus With Prednisolone for KHE and KMP Sirolimus (RAPAMUNE) - Kaposiform Hemangioendothelioma (KHE), Kasabach Merritt Phenomenon | Phase 2 / Phase 3 | Recruiting | Yi Ji | 76 | 2026-06-16 | 2026-06-18 |
Kaposiform Hemangioendothelioma (1) · Kasabach-Merritt Syndrome (1)
Sirolimus (1)
China (1)
PMID 22871490, PMID 28486787, PMID 31489702, PMID 32014025, PMID 33580918, PMID 34082006, PMID 34273457, PMID 35030255, PMID 3691614, PMID 3936944, PMID 39831682, PMID 40107509, PMID 41831614